Author:
Bennett Hayley,McEwan Phil,Hamilton Karina,O’Reilly Karl
Funder
Otsuka Pharmaceutical Europe Ltd
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Ong AC, Devuyst O, Knebelmann B, Walz G, ERA-EDTA Working Group for Inherited Kidney Diseases. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385(9981):1993–2002.
2. Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA registry. Nephrol Dial Transplant. 2014;29(suppl 4):iv15–25.
3. Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant. 2016;31(3):337–48.
4. Pharmaceuticals and medical devices agency. Review report: Samsca 2014 [28 Feburary 2018]. Available from:
http://www.pmda.go.jp/files/000208511.pdf
5. European Medicines Agency. European public assessment report - product information: Jinarc (tolvaptan) 2017 [16 January 2018]. Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002788/WC500187921.pdf
.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献